Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Annals of Oncology

• Publication date

  2013-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdt177PMID 23676418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.

  2011cited by this paper
• Targeting RET Receptor Tyrosine Kinase Activation in Cancer

  2010cited by this paper
• Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

  2009cited by this paper
• Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

  2009cited by this paper
• New therapeutic approaches to treat medullary thyroid carcinoma

  2008cited by this paper
• We should desist using RECIST, at least in GIST.

  2007cited by this paper
• Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

  2007cited by this paper
• The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

  2007cited by this paper
• Spontaneous circadian fluctuations of prostate specific antigen and prostatic acid phosphatase serum activities in patients with prostatic cancer

  2004cited by this paper
• Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma.

  2002cited by this paper
• Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Disappearance Rate of Serum Calcitonin after Total Thyroidectomy for Medullary Thyroid Carcinoma

  1994cited by this paper
• RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer.

  1994cited by this paper
• CEA-related antigens: molecular biology and clinical significance.

  1985cited by this paper
• Early diagnosis and treatment of medullary thyroid carcinoma.

  1985cited by this paper
• Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow‐up of medullary thyroid carcinoma

  1984cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Patient-derived medullary thyroid cancer organoids: a potential model for mechanistic studies on diagnostics and therapy

  2025influential citation
• Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin

  2024cites this paper
• Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients

  2023cites this paper
• Other markers of medullary thyroid cancer, not only calcitonin.

  2023cites this paper
• Patient-Derived Medullary Thyroid Cancer Organoids; a Model for Patient-tailored Drug and PET-Tracer Screening

  2023influential citation
• The role of procalcitonin in the follow-up of medullary thyroid cancer

  2022cites this paper
• Cancer: slaying the nine-headed Hydra

  2022cites this paper
• Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma

  2021cites this paper
• Cancer of Unknown Primary in the Molecular Era.

  2021cites this paper
• What's New in Molecular Targeted Therapies for Thyroid Cancer?

  2021cites this paper
• Highly sensitive protein detection using recombinant spores and lateral flow immunoassay

  2021cites this paper
• Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.

  2021cites this paper
• Role of tissue and circulating microRNA and DNA as biomarkers in medullary thyroid cancer.

  2020cites this paper
• Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?

  2019cites this paper
• Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients.

  2018cites this paper
• Calcitonin and Carcinoembryonic Antigen for the Diagnosis and Management of Medullary Thyroid Carcinoma

  2018cites this paper
• Non-mammalian models of multiple endocrine neoplasia type 2.

  2018cites this paper
• A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11

  2017cites this paper
• Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib

  2017cites this paper
• Utility of proGRP as a tumor marker in the medullary thyroid carcinoma

  2017cites this paper
• Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib

  2017cites this paper
• Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine

  2017cites this paper
• Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.

  2017cites this paper
• Metastatic Medullary Thyroid Cancer, Somatostatin Analogues and Markers

  2016cites this paper
• Sunitinib for the treatment of thyroid cancer

  2016cites this paper
• Management of advanced medullary thyroid cancer.

  2016cites this paper
• Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B

  2016cites this paper
• RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients

  2016cites this paper
• Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience

  2016cites this paper
• Tumor Markers Currently Utilized in Cancer Care

  2015cites this paper
• Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment

  2015cites this paper
• Mechanisms of RET signaling in cancer: current and future implications for targeted therapy.

  2014cites this paper
• Progression of medullary thyroid cancer in RET carriers of ATA class A and C mutations.

  2014cites this paper
• [Targeted therapies, prognostic and predictive factors in endocrine oncology].

  2013cites this paper